T. Rowe Price Associates
KRON

T. Rowe Price Associates’s Kronos Bio KRON Stock Holding History

T. Rowe Price Associates’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-163,592
Closed -$265K – 2940
2022
Q4 		$265K Sell
163,592
-7,594
-4% -$17.5K ﹤0.01% 2417
2022
Q3 		$575K Sell
171,186
-228,125
-57% -$1.03M ﹤0.01% 2054
2022
Q2 		$1.45M Sell
399,311
-554
-0.1% -$2.51K ﹤0.01% 1732
2022
Q1 		$2.89M Sell
399,865
-1,133,697
-74% -$9.67M ﹤0.01% 1577
2021
Q4 		$20.8M Sell
1,533,562
-239,621
-14% -$3.75M ﹤0.01% 1277
2021
Q3 		$37.2M Buy
1,773,183
+5,512
+0.3% +$118K ﹤0.01% 1118
2021
Q2 		$42.3M Sell
1,767,671
-339,837
-16% -$8.6M ﹤0.01% 1087
2021
Q1 		$60.3M Sell
2,107,508
-6,070
-0.3% -$178K 0.01% 937
2020
Q4 		$61.7M Buy
+2,113,578
New +$66.3M 0.01% 880

Other funds holding KRON

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

T. Rowe Price Associates's KRON Position: Q1 2023 in Review

T. Rowe Price Associates sold out of Kronos Bio (KRON) in Q1 2023, closing a stake of 163,592 shares — an estimated $265K sold.

T. Rowe Price Associates first reported a position in KRON in Q4 2020 and held it in 9 quarters. The position peaked at $61.7M in Q4 2020. 87 funds tracked by Wall St. Rank hold KRON as of Q1 2023.

  • T. Rowe Price Associates reported no remaining Kronos Bio position as of Q1 2023 after selling out during the quarter.
  • T. Rowe Price Associates sold 163,592 Kronos Bio shares in Q1 2023, an estimated $265K.
  • T. Rowe Price Associates first reported a position in Kronos Bio in Q4 2020 and held it in 9 quarters.
  • T. Rowe Price Associates's Kronos Bio position peaked at $61.7M in Q4 2020.
  • 87 funds tracked by Wall St. Rank held Kronos Bio as of Q1 2023.

Based on T. Rowe Price Associates's 13F filing for Q1 2023, filed 15 May 2023.